Moreover, the geographical differences in PCa screening with PSA have been shown to correlate strongly with the observed differences in PCa incidence [23, 24], but differences in screening rates cannot fully explain the variation in PCa incidence, since these differences were observed before PSA-testing became available [24]. The gene discussed is KLK3; the disease is posterior cortical atrophy.